Literature DB >> 12203361

Follistatin overexpression in rodent liver tumors: a possible mechanism to overcome activin growth control.

Walter Rossmanith1, Monika Chabicovsky, Bettina Grasl-Kraupp, Barbara Peter, Elisabeth Schausberger, Rolf Schulte-Hermann.   

Abstract

The activin-follistatin system is a potent growth regulatory system of liver tissue homeostasis. Activin A inhibits hepatocellular DNA synthesis and induces cell death. Follistatin binds activin and sequesters it from the signaling pathway. Consistently, follistatin has been reported to act as an inducer of DNA synthesis in the liver. Using RNase protection analysis, we studied the expression of follistatin in rat and mouse liver tumors as a possible mechanism to overcome activin growth control. Approximately 40% of the tumors (nine of 24 each), most of them hepatocellular carcinomas, displayed increased levels of follistatin mRNA when compared to tumor-surrounding liver tissue. The degree of overexpression was highly variable but independent of the carcinogen treatment that animals had received. It was also independent from the histological stage of malignancy and further found in rat liver adenomas. Follistatin expression was also observed in cell lines derived from human hepatocellular carcinomas. Overexpression of follistatin may represent a unique strategy of hepatic tumors to overcome the inhibitory action of a growth factor, activin, by decreasing its local bioavailability. Copyright 2002 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12203361     DOI: 10.1002/mc.10068

Source DB:  PubMed          Journal:  Mol Carcinog        ISSN: 0899-1987            Impact factor:   4.784


  12 in total

1.  Evaluation of annexin A2 and as potential biomarkers for hepatocellular carcinoma.

Authors:  Nevine El-Abd; Amal Fawzy; Tamer Elbaz; Sherif Hamdy
Journal:  Tumour Biol       Date:  2015-07-20

2.  The effect of oncoprotein v-erbA on thyroid hormone-regulated genes in hepatocytes and their potential role in hepatocellular carcinoma.

Authors:  Tereza Ventura-Holman; Abulkhair Mamoon; Maria C Subauste; Jose S Subauste
Journal:  Mol Biol Rep       Date:  2010-06-23       Impact factor: 2.316

3.  Activins and follistatins: Emerging roles in liver physiology and cancer.

Authors:  Emanuel Kreidl; Deniz Oztürk; Thomas Metzner; Walter Berger; Michael Grusch
Journal:  World J Hepatol       Date:  2009-10-31

Review 4.  Clinical and Therapeutic Implications of Follistatin in Solid Tumours.

Authors:  Lei Shi; Jeyna Resaul; Sioned Owen; Lin Ye; Wen G Jiang
Journal:  Cancer Genomics Proteomics       Date:  2016 11-12       Impact factor: 4.069

Review 5.  Follistatin as potential therapeutic target in prostate cancer.

Authors:  Maria Vittoria Sepporta; Francesca Maria Tumminello; Carla Flandina; Marilena Crescimanno; Marco Giammanco; Maurizio La Guardia; Danila di Majo; Gaetano Leto
Journal:  Target Oncol       Date:  2013-03-01       Impact factor: 4.493

Review 6.  Activins and activin antagonists in hepatocellular carcinoma.

Authors:  Alev Deli; Emanuel Kreidl; Stefan Santifaller; Barbara Trotter; Katja Seir; Walter Berger; Rolf Schulte-Hermann; Chantal Rodgarkia-Dara; Michael Grusch
Journal:  World J Gastroenterol       Date:  2008-03-21       Impact factor: 5.742

7.  Peroxisome proliferator-activated receptor gamma down-regulates follistatin in intestinal epithelial cells through SP1.

Authors:  Brian M Necela; Weidong Su; E Aubrey Thompson
Journal:  J Biol Chem       Date:  2008-09-03       Impact factor: 5.157

8.  BRCA1 regulates follistatin function in ovarian cancer and human ovarian surface epithelial cells.

Authors:  Tejaswita M Karve; Anju Preet; Rosie Sneed; Clara Salamanca; Xin Li; Jingwen Xu; Deepak Kumar; Eliot M Rosen; Tapas Saha
Journal:  PLoS One       Date:  2012-06-01       Impact factor: 3.240

9.  Identification of proteins involved in neural progenitor cell targeting of gliomas.

Authors:  Karin Staflin; Thole Zuchner; Gabriella Honeth; Anna Darabi; Cecilia Lundberg
Journal:  BMC Cancer       Date:  2009-06-26       Impact factor: 4.430

10.  AFP, PIVKAII, GP3, SCCA-1 and follisatin as surveillance biomarkers for hepatocellular cancer in non-alcoholic and alcoholic fatty liver disease.

Authors:  Gary Beale; Dipankar Chattopadhyay; Joe Gray; Stephen Stewart; Mark Hudson; Christopher Day; Paolo Trerotoli; Gianluigi Giannelli; Derek Manas; Helen Reeves
Journal:  BMC Cancer       Date:  2008-07-18       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.